5-IAI

5-IAI
Systematic (IUPAC) name
5-iodo-2,3-dihydro-1H-inden-2-amine
Clinical data
Pregnancy
category
  • ?
Routes of
administration
Oral, Insufflated, Rectal
Legal status
  • Uncontrolled
Identifiers
CAS Number 132367-76-1 N
ATC code none
PubChem CID 131506
ChemSpider 116224 YesY
UNII 7X16E45Y1X YesY
Chemical data
Formula C9H10IN
Molar mass 259.087 g/mol
 NYesY (what is this?)  (verify)

5-Iodo-2-aminoindane (5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine.[1] It was developed in the 1990s by a team led by David E. Nichols at Purdue University.[2] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans.[2] Unlike related aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats, but is substantially less toxic than its corresponding amphetamine homologue pIA, with the damage observed barely reaching statistical significance.[1]

See also

References

  1. 1 2 Johnson MP, Conarty PF, Nichols DE (July 1991). "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues". European Journal of Pharmacology 200 (1): 9–16. doi:10.1016/0014-2999(91)90659-E. PMID 1685125.
  2. 1 2 Nichols DE, Johnson MP, Oberlender R (January 1991). "5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine". Pharmacology, Biochemistry, and Behavior 38 (1): 135–9. doi:10.1016/0091-3057(91)90601-W. PMID 1826785.


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.